Introduction {#s1}
============

Dengue virus (DENV) is the most common and widespread arboviral infection on Earth ([@B1]). DENV is a flavivirus composed of four antigenically distinct serotypes that causes a spectrum of disease ranging from mild febrile illness to death. Antibody-dependent enhancement during secondary DENV infections can exacerbate disease leading to dengue shock syndrome (DSS), dengue hemorrhagic fever (DHF), and dengue break-bone fever ([@B2]). Though these viruses occupy the same ecological niche, co-infections are rarely reported.

DENV is endemic to Pakistan along with West Nile virus (WNV), Japanese encephalitis virus (JEV), and Chikungunya virus (CHIKV) ([@B3]--[@B5]). These viruses have overlapping syndromes which complicates diagnosis leading to poorly defined epidemiology. Serological diagnosis is difficult due to antigenic cross reactivity of flaviviruses ([@B6]). Nucleic acid detection is equally as difficult due to the short duration of detectable viremia ([@B7]). Fortunately, advances in flaviviral diagnostics have significantly improved accurate and timely diagnosis which can have a direct and positive effect on patient care. For instance, several ELISA and lateral flow assays are commercially available that can simultaneously detect DENV antigen, IgM and IgG antibodies ([@B8]--[@B11]). This can help health care providers easily distinguish between early, primary, and secondary infections.

Though all four DENV serotypes cocirculate in nature, the clinical manifestations of these serotypes are undefined in Pakistan as well as the contribution of secondary and co-infections on the presentation of severe manifestations of disease. Here we describe a population of patients diagnosed with DENV over a 2-year period. Patients were divided according to their infecting serotype to document serotype-associated clinical features that might help differentiate one serotype from another in a primary health care setting.

Methods {#s2}
=======

Ethics Statement
----------------

Adult participants or parents/legal guardians of minors were enrolled under informed consent procedures which were reviewed and approved by the Ethics Review Committee at Aga Khan University (\#3183-PAT-ERC-14) and the Institutional Review Board at the University of Florida (\#201500908). All enrolled subjects gave written informed consent in accordance with the Declaration of Helsinki.

Patient Samples
---------------

A cross-sectional, observational study was performed to document the circulation of various arboviruses in the Sindh region of Pakistan spanning 2015--2017 ([@B4]). Patients presenting with the CDC clinical description of arboviral disease including findings of rash, headache, arthralgia, myalgia, gastro-intestinal distress, acute hemorrhagic fever, acute flaccid paralysis, encephalitis, meningitis, and/or unexplained fever were recruited ([@B4]). Patients younger than 10 and older than 90 years of age were excluded. In total, 997 patients were enrolled, and clinical and demographic information was recorded. All enrolled patients provided a serum specimen which was screened for DENV NS1 antigen. 168 NS1 positive patients were evaluated for DENV serotype via RT-PCR.

Case Definitions
----------------

All 4 DENV serotypes co-circulate in Pakistna and since secondary and co-infections can cause more severe forms of disease, it was necessary to classify RT-PCR + patients by their infection status. Primary infection was defined as NS1 AND RT-PCR positive but negative for neutralizing IgG by PRNT using patient specimen collected upon study enrollment. Secondary infection was defined as NS1 positive AND RT-PCR positive AND neutralizing IgG positive by PRNT using patient specimen collected upon study enrollment. Co-infections were defined as NS1 AND RT-PCR positive for 2 DENV serotypes but negative for neutralizing IgG by PRNT using patient specimen collected upon study enrollment.

Serology
--------

Primary DENV screening in patients was performed using a commercial ELISA (Panbio Dengue Early Rapid Test NS1 antigen capture test (Alere, Waltham, MA), following manufacturer\'s instructions. IgM ELISA was performed to rule out co-infection with WNV, JEV, CHIKV, and ZIKV with commercially purchased IgM ELISA assays including CHIKjj Detect, JE Detect, ZIKV Detect all from InBios International (Seattle, USA) per manufacturer\'s instructions. Plaque reduction neutralization testing (PRNT) was performed on all RT-PCR + patients as described elsewhere to determine if patients had previous DENV exposure ([@B4], [@B12]). Briefly, 100 infectious units (i.u.) of virus (calculated from stock virus titer) in PBS were incubated for 1 h at 37°C with 1:10 dilution of subject serum. Assay controls included 100 i.u. of virus in PBS, 100 i.u. of virus with 1:10 dilution of positive control serum, and a mock infected control consisting of PBS. Cells with inoculum were incubated at 37°C for 1 h after which the inoculum was removed and an overlay consisting of MEM with 10% FBS and 0.5% methylcellulose. Assays were incubated 3--7 days, depending on serotype, at 37°C after which monolayers were stained with Coomassie blue.

Viruses used included: DENV-1 (TS-SMAN), DENV-2 (NGC), DENV-3 (H87), and DENV-4 (H241). Viruses were obtained from BEI Resources and expanded once in Vero E6 cells. Patients were classified has having prior DENV exposure when there was neutralization of at least 80% at the 1:10 serum dilution. Specimens that neutralized more than 1 serotype were diluted out by 4-fold dilutions. The serotype with the most neutralization at the greatest dilution was identified as the infecting serotype.

Nucleic Acid Tests
------------------

DENV primers and probes from the CDC RT-PCR assay were used to detect the NS5, envelope, or prM protein depending on serotype ([@B4], [@B13]). Briefly, RNA was isolated from human serum samples using a commercial viral RNA extraction kit (QIAamp viral RNA kit, Qiagen, Valencia, CA). RNA was reverse transcribed to cDNA (iScript cDNA Synthesis Kit, Bio-Rad, Hercules, California) and real-time PCR was performed using a commercial master mix (BioRad iTaq Universal Probes Supermix, BioRad, Hercules, CA, USA) and a commercial real-time PCR machine (BioRad CFX 96, BioRad) ([@B4]).

Statistical Analysis
--------------------

RT-PCR-positive patients were divided into 3 groups for statistical analysis which included primary infection, co-infection, and secondary infection per the case definitions above. We did not include patients with co-infections or secondary infections in the primary analysis because research has shown that these patients can have more severe manifestations of disease than patients with a primary infection with a single serotype ([@B2], [@B14], [@B15]). Clinical laboratory values were compared against the normal reference range for the appropriate sex as needed (i.e., hematocrit). Statistical analyses were performed on clinical data using MedCalc version 17.9.7 -- 64-bit. Logistic regression for dichotomous independent variables were performed. Odds ratios were calculated with 95% confidence intervals. Ratios with a *p* \< 0.05 were considered significant. When comparing serotypes with each other in respect to variables such as sex ratios, or age distribution, an ANOVA with Laverne\'s test, Tukey-Kramer *post-hoc* and Chi square for normal distribution was performed. When appropriate, pairwise comparisons were performed with a Student\'s *T*-test.

Results {#s3}
=======

Patient Characteristics
-----------------------

A total of 168 NS1 positive patients were identified out of 997 subjects recruited from the Sindh province of Pakistan during 2015--2017. The vast majority of these 168 patients were recruited from Karachi, the most populous city in the region. Patients were also recruited from Mirpurkhas, Larkana, and Sukkur ([Figure 1](#F1){ref-type="fig"}). A small number of patients were enrolled in Karachi from individuals visiting from other regions such as the Western province of Balochistan and the area around Lahore ([Figure 1](#F1){ref-type="fig"}). These cases occurred throughout the year irrespective of holidays or festivals. All serotypes of DENV were identified year-round with the majority of cases identified during the autumn months ([Figure 2](#F2){ref-type="fig"}). The average age of patients was 33 years and an equal proportion of males and females were observed ([Figure 3](#F3){ref-type="fig"}). There was no significant difference between the serotypes for sex or age ([Figure 3](#F3){ref-type="fig"}). Of the 168 NS1 positive patients, 91 were serotyped via RT-PCR. The remaining 77 patients were negative for all 4 DENV serotypes via RT-PCR and subtyping via plaque reduction neutralization test was performed. However, serological cross-reactivity prevented diagnosis thus, these patients were excluded from the analysis. DENV2 (*n* = 59) was the most commonly identified serotype by RT-PCR closely followed by DENV1 (*n* = 23). DENV3 was identified in 15 patients and DENV4 identified in 7 patients. All RT-PCR positive patients were also negative via IGM ELISA for JEV, WNV, CHIKV, and Zika viruses (data not shown).

![The locations of subjects infected with dengue virus during 2015--2017. The majority of cases were identified from Karachi.](fpubh-08-00287-g0001){#F1}

![The sustained co-circulation of 4 dengue serotypes in the Sindh region of Pakistan 2015--2017. Data presented represents all RT-PCR positive samples including co-infections and secondary infections.](fpubh-08-00287-g0002){#F2}

![Age and gender of individuals infected with dengue virus. The data represents all primary and secondary infections.](fpubh-08-00287-g0003){#F3}

Of the 23 DENV1 subtyped patients, 14 were RT-PCR positive for a second DENV serotype and 1 was identified as a secondary infection ([Table S1](#SM1){ref-type="supplementary-material"}). Of the 59 patients that were RT-PCR positive for DENV2, 12 had co-infections and 5 had secondary infections ([Table S1](#SM1){ref-type="supplementary-material"}). Of 12 patients RT-PCR positive for DENV 3, 2 were also positive for DENV 1 co-infections and 1 patient was positive for secondary DENV infection ([Table S1](#SM1){ref-type="supplementary-material"}). Seven individuals were positive for DENV4 via RT-PCR of which one patient was co-infected with DENV2 and another patient was positive for a secondary DENV infection ([Table S1](#SM1){ref-type="supplementary-material"}).

Clinical Manifestations
-----------------------

Temperature, heart rate, and blood pressure readings were recorded upon enrollment. There were no significant manifestations for any of the serotypes ([Table 1](#T1){ref-type="table"}). Most patients from all DENV serotypes exhibited mean heart rates that were within the normal range of 60--100 beats per minute with no significant difference between serotypes ([Table 1](#T1){ref-type="table"}). Average blood pressure readings were within the normal range and \<20% of patients (for all serotypes) exhibited abnormal readings. Average temperatures for DENV1 and DENV2 were 37.4 and 37.5°C, respectively ([Table 1](#T1){ref-type="table"}). Average temperatures for DENV3 and DENV4 were higher with average enrollment temperatures recorded at 38.0 and 38.2°C, respectively, with no significant difference between serotypes ([Table 1](#T1){ref-type="table"}).

###### 

Vital statistics for patients with primary DENV infections.

                       **Dengue 1**      **Dengue 2**      **Dengue 3**     **Dengue 4**
  -------------------- ----------------- ----------------- ---------------- -----------------
  Heart rate (bpm)     98 (56--133)      94 (58--152)      97 (72--140)     100 (79--138)
  Systolic (mmHg)      122 (92--160)     118 (88--176)     115 (100--134)   118 (105--122)
  Diastolic (mmHg)     81 (55--112)      71 (32--92)       71 (56--83)      69 (54--84)
  Temperature (°C)     37.4 (36.4--38)   37.5 (36--40.5)   38 (36.5--39)    38.2 (38--38.6)
  Respirations (bpm)   20 (17-22)        20.3 (17-27)      21 (20--24)      20 (18--22)

*These patients were NS1 and RT--PCR positive for only one serotype and negative for DENV neutralizing antibodies via PRNT*.

We performed logistic regression to obtain odds ratios for a series of clinical hematological profiles commonly evaluated upon admission to hospital. Over 60% of patients infected with DENV1 exhibited elevated AST and ALT ([Table 2](#T2){ref-type="table"}). DENV1 patients were 2.0 times more likely to have elevated AST and 1.86 times more likely to have elevated ALT when compared with the other 3 serotypes ([Table 2](#T2){ref-type="table"}). Total lymphocyte counts were elevated in many patients however, DENV-3 infected individuals were 2.89 times more likely to exhibit elevated lymphocyte counts ([Table 2](#T2){ref-type="table"}). Thrombocytopenia is a common sign of DENV infection which was reported for the majority of patients for all serotypes though 100% of DENV1 and 80% of DENV4 infected patients exhibited low platelet counts and were at least 2.0 times more likely than any other serotype to have thrombocytopenia than the other serotypes ([Table 2](#T2){ref-type="table"}). Low hemoglobin counts were reported for 16% of DENV2 infected patients and 14% of DENV3 infected patients but not in DENV1 or DENV4 patients ([Table 2](#T2){ref-type="table"}). Below normal hematocrit levels were reported for 62% of DENV2 patients and 75% of DENV3 patients while no DENV1 and only 1 DENV4 infected patient had below normal hematocrit levels ([Table 2](#T2){ref-type="table"}). When compared with the other serotypes, DENV3 patients were twice as likely to exhibit low hematocrit levels ([Table 2](#T2){ref-type="table"}).

###### 

Hematological profiles for patients with primary DENV infections.

                        **Dengue 1**        **Dengue 2**         **Dengue 3**        **Dengue 4**                                                                        
  --------------------- ------------------- -------------------- ------------------- ------------------- ------------------- ------------------- ----------------------- -------------------
  AST (IU/L)            228 (59--406)       2.0 (0.19 20.14)     139 (27-570)        0.75 (0.13--4.09)   114 (41--288)       0.83 (0.12--5.47)   Sample size too small   
                        6 (86%)                                  12 (75%)                                6 (50%)                                                         
  ALT (IU/L)            101 (20--247)       1.86 (0.38--8.98)    146 (16--751)       0.83 (0.25--2.72)   83.3 (28--277)      0.75 (0.17--3.29)   86.2 (28--221)          1.0 (0.12--7.81)
                        5 (62%)                                  11 (48%)                                4 (33%)                                 1 (16.6%)               
  TLC (10^9^/L)         41 (12.9--52.7)     1.39 (0.3--6.41)     30 (4--55.5)        0.56 (0.2--1.56)    27.1 (8.2--48.1)    2.89 (0.7--11.87)   15.8 (3.5--24.1)        0.51 (0.07--3.27)
                        5 (62%)                                  19 (46%)                                9 (75%)                                 1 (20%)                 
  Platelets (10^9^/L)   46.5 (12-133)       **546**^**E+006**^   119 (19--330)       370^E+015^          134 (3--258)        0.94 (0.24--3.57)   114 (43--204)           2.0 (0.2--19.09)
                        8 (100%)                                 23 (57%)                                8 (67%)                                 4 (80%)                 
  Hemoglobin (gm/dL)    15.4 (12.2--17.2)   7.14^E−009^          13.5 (9.2--17.4)    1.81 (0.33--9.89)   13.5 (10.5--18.1)   1.43 (0.25--8.18)   13.8 (12.1--14.8)       7.14^E−009^
                        0 (0%)                                   6 (16%)                                 2 (14%)                                 0 (0%)                  
  Hematocrit            44.8 (36--48.2)     0.10 0.009--1.09     39.2 (32.7--46.9)   1.04 (0.23--4.7)    37.5 (31.4--42.8)   2.0 (0.18--22.05)   40.2 (36.6--42.6)       629^E+006^
                        0 (0%)                                   10 (62%)                                3 (75%)                                 1 (25%)                 

*These patients were NS1 and RT-PCR positive for only one serotype and negative for DENV neutralizing antibodies via PRNT. Bold font indicates statistical significance. OR, odds ratio; CI, confidence interval; N, number of patients*.

We performed logistic regression to obtain odds ratios for a series of common DENV-associated symptoms in order to determine if there were serotype-associated symptoms. Myalgia was a common symptom of all serotypes with at least 45% of patients reporting body aches ([Table 3](#T3){ref-type="table"}). Nausea and vomiting were also common complaints with at least 62% of all patients, for all serotypes, reporting these symptoms ([Table 3](#T3){ref-type="table"}). Eye pain was rarely reported with only 7% of DENV2 patients complaining of this symptom ([Table 3](#T3){ref-type="table"}). Overall, at least 58% of all patients were given a provisional diagnosis of dengue fever with 75% of DENV1 patients obtaining this diagnosis ([Table 3](#T3){ref-type="table"}). For patients without a provisional diagnosis of dengue fever, antibiotics were usually prescribed (*P* = 0.0007) ([Table 3](#T3){ref-type="table"}).

###### 

Symptoms for patients with primary DENV infections.

                               **Dengue 1**                **Dengue 2**        **Dengue 3**         **Dengue 4**
  ---------------------------- --------------------------- ------------------- -------------------- --------------------
  Arthralgia                   0.0                         4.0 (0.45--35.35)   2.34^E−009^          2.33 (0.22--24.4)
                               0                           6 (14.2%)           0                    1 (20%)
  Myalgia                      1.11 (0.25--4.84)           0.76 (0.28--2.05)   1.11 (0.31--3.89)    1.71 (0.26--10.93)
                               4 (50%)                     19 (45.2%)          6 (50%)              3 (60%)
  Headache                     0.45 (0.06--2.91)           1.02 (0.37--2.8)    0.69 (0.15--3.09)    6.78 (0.71--64.42)
                               2 (25%)                     17 (40.4%)          4 (33.3%)            4 (80%)
  Rash                         0.74 (0.08--6.82)           0.59 (0.15--2.28)   1.10 (0.2--5.99)     4.25 (0.61--29.520
                               1 (12.5%)                   5 (12%)             2 (16.6%)            2 (40%)
  Hemorrhagic manifestations   1.63 (0.31--10.75)          1.23 (0.33--4.61)   0.90 (0.17--4.76)    6.78^E−009^
                               2 (25%)                     8 (19%)             2 (16.6%)            0
  Fever ≥38°C                  **0.08 (0.01**--**0.75)**   1.50 (0.54--4.15)   0.92 (0.24--3.390    618^E+006^
                               1 (12.5%)                   23 (54.7%)          6 (50%)              5 (100%)
  Nausea/vomiting              0.62 (0.13--2.89)           1.32 (0.44--3.92)   0.75 (0.19--2.86)    4.3 (0.23--78.63)
                               5 (62.5%)                   31 (73.8)           8 (66.6%)            4 (80%)
  Burning micturition          0.79 (0.08--7.25)           0.54 (0.13--2.09    2.28 (0.49--10.53)   1.47 (0.14--14.72)
                               1 (12.5%)                   5 (12%)             3 (25%)              1 (20%)
  Neurologic symptoms          2.37^E−009^                 3.1 (0.61--15.88)   1.02 (0.19--5.47)    6.92^E−009^
                               0                           9 (21.4%)           2 (16.6%)            0
  Dengue fever diagnosis       1.62 (0.27 to 9.49)         0.96 (0.33--2.8)    0.87 (0.22--3.38)    0.73 (0.08--6.58)
                               6 (75%)                     27 (62.4%)          7 (58.3%)            3 (60%)
  Antibiotics prescribed       0.40 (0.07--2.15)           1.42 (0.50--4.03)   1.13 (0.3--4.2)      0.88 (0.13--5.670
                               2 (25%)                     18 (42.8%)          5 (41.6%)            2 (40%)
  Eye pain                     0.0                         204^E+006^          6.88^E−009^          0.0
                               0                           3 (7%)              0                    0
  Fever ≥38.5°C                **1.83**^**E−009**^         0.91 (0.26--2.19)   2.78 (0.7--9.1)      1.55 (0.53--22.76)
                               0                           12 (26.2%)          6 (50%)              2 (40%)

*Logistic analysis was performed in which a single serotype was compared against the other serotypes. These patients were NS1 and RT-PCR positive for only one serotype and negative for DENV neutralizing antibodies via PRNT. Bold font indicates statistical significance. OR, odds ratio; CI, confidence interval; N, number of patients*.

The data indicates that patients with DENV1 infections were less likely to report dengue-associated symptoms that any other serotype. These patients had fewer complaints of arthralgia, myalgia, rash, nausea, and eye pain ([Table 3](#T3){ref-type="table"}). These patients were also significantly less likely to have a fever \>38°C (*P* = 0.0261) ([Table 3](#T3){ref-type="table"}). Patients with DENV2 infections were 4.0 times more likely to complain of arthralgia than the other serotypes ([Table 3](#T3){ref-type="table"}). DENV2 patients were also 3.1 times more likely to exhibit neurological symptoms including, altered mental status, confusion, acute disseminated encephalomyelitis, or encephalitis ([Table 3](#T3){ref-type="table"}). Patients with DENV3 infections were unlikely to complain of arthralgia or other DENV-associated symptoms ([Table 3](#T3){ref-type="table"}). These patients were 2.28 times more likely to complain of burning micturition and 2.78 times more likely to have a fever \>38.5°C than the other serotypes ([Table 3](#T3){ref-type="table"}). Nearly 80% of patients with DENV4 infection were most likely to exhibit dengue-like symptoms with patients being 6.78, 4.25, and 4.3 time more likely to report headache, rash, and nausea, respectively ([Table 3](#T3){ref-type="table"}).

Co-infections
-------------

Co-infections of 2 different DENV serotypes were detected by RT-PCR in 14 individuals ([Table S1](#SM1){ref-type="supplementary-material"}). We performed logistic regression to obtain odds ratios, comparing these patients with all patients with primary infections. Research has shown that co-infections can produce more severe manifestations of disease ([@B15]). Thus, our goal was to determine if there were any clinical features that might be associated with infection with more than one DENV serotype. For our patients, 1 individual was co-infected with DENV serotypes 2 and 4. This patient had a fever of 39.4°C and hemorrhagic manifestations. This individual developed acute disseminated encephalomyelitis (ADEM). Three patients were co-infected with DENV serotypes 2 and 3 and 10 patients were co-infected with DENV1 and DENV2 ([Table S1](#SM1){ref-type="supplementary-material"}). These patients had relatively mild manifestations of dengue fever complaining of headache, myalgia, and nausea. Patients with co-infections were indistinguishable from patients with a single infection on the basis of their clinical manifestations ([Table 4](#T4){ref-type="table"}). Overall, patients with co-infections exhibited the same clinical profiles as patients infected with a single serotype ([Table 4](#T4){ref-type="table"}). Co-infected patients were significantly less likely to have thrombocytopenia or low hematocrit levels than patients infected with a single serotype ([Table 4](#T4){ref-type="table"}).

###### 

Symptoms and hematological profiles for patients with DENV co-infections and secondary infections.

                               **Co-infection**        **Secondary infection**
  ---------------------------- ----------------------- --------------------------
  Arthralgia                   2.85 (0.72--11.31)      1.42 (0.14--13.65)
                               4 (26.6%)               1 (12.5%)
  Myalgia                      0.36 (0.1--1.24)        1.45 (0.3--7.02)
                               4 (26.6%)               4 (50%)
  Headache                     0.88 (0.28--2.73)       3.70 (0.66--20.49)
                               6 (40%)                 5 (62.5%)
  Rash                         0.77 (0.15--3.92)       0.90 (0.09--8.3)
                               2 (13.3%)               1 (12.5%)
  Hemorrhagic manifestations   0.30 (0.036--2.54)      6.72^E−009^
                               1 (6.6%)                0
  Fever ≥38°C                  0.77 (0.25--2.33)       1.03 (0.27--3.92)
                               10 (71.4%)              7 (87.5%)
  Nausea/vomiting              0.50 (0.16--1.56)       0.79 0.13--4.68
                               8 (53.3%)               5 (62.5%)
  Burning micturition          2.23^E−009^             6.97^E−009^
                               0                       1 (12.5%)
  Neurologic symptoms          0.34 (0.04--2.84)       0.84 (0.09--7.76)
                               1 (6.6%)                1 (12.5%)
  Dengue fever diagnosis       1.12 (0.34--3.64)       3.07 (0.34--27.11)
                               9 (60%)                 5 (62.5%)
  Antibiotics prescribed       1.71 (0.56--5.18)       1.3 (0.31--5.34)
                               6 (40%)                 0
  Eye pain                     6.81^E−009^             3.55 0.31--39.70
                               0                       1 (12.5%)
  ALT                          1.25 (0.29--5.280       5.0 (0.53--46.35)
                               3 (20%)                 2 (25%)
  AST                          **0.22 (0.06--0.83)**   2.21^E−010^
                               5 (33.3%)               5 (62.5%)
  Systolic                     0.51 (0.05--4.41)       7.15^E−009^
                               1 (6.6%)                0
  Diastolic                    0.0                     **(25.60 1.96--333.56)**
                               0                       2 (25%)
  Heart rate                   2.62 (0.78--8.81)       1.68 0.34--8.24)
                               7 (46.6%)               5 (62.5%)
  Hemoglobin                   2.83 (0.6--13.28)       3.31 (0.51--21.13)
                               3 (20%)                 1 (12.5%)
  Hematocrit                   **0.20 (0.04--0.91)**   1.03^E−009^
                               3 (20%)                 2 (25%)
  PLT                          **0.28 (0.09--0.89)**   0.35 (0.07--1.74)
                               7 (46.6%)               6 (75%)
  TLC                          561^E+006^              0.80 (0.04--13.44)
                               5 (33.3%)               2 (25%)

*Co-infected patients were NS1 and RT-PCR positive for at least 2 serotypes and negative for DENV neutralizing antibodies via PRNT. Patients with secondary infections were NS1 positive and positive for one serotype via RT-PCR and possessed DENV neutralizing antibodies as determined by PRNT. Logistic analysis was performed in which co-infected or secondary infections were compared against primary DENV infections. Bold font indicates statistical significance. OR, odds ratio; CI, confidence interval; N, number of patients*.

Secondary Infections
--------------------

We performed logistic regression to obtain odds ratios comparing individuals with secondary DENV infections with all individuals with primary infections. Our goal was to identify any significant clinical features that might be associated with secondary infections. Secondary DENV infection commonly result in more sever disease including DHF and DSS ([@B2], [@B14]--[@B16]). All RT-PCR positive serum was used for PRNT assay against the 3 respective RT-PCR negative serotypes. Secondary DENV infections were identified in 8 individuals by PRNT ([Table S1](#SM1){ref-type="supplementary-material"}). One patient PCR positive for DENV1 had high titers of neutralizing antibodies to DENV2. Five individuals with active DENV2 infections had high neutralizing titers against DENV1. One patient with an active DENV3 infection had high titers of neutralizing antibodies against DENV2. One individual with an active DENV4 infection had previous exposure to DENV1. None of the patients with secondary infection exhibited symptoms consistent with DHF or DSS in fact, these patients were indistinguishable from patents with primary infections of any serotype on the basis of their clinical manifestations ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}).

Discussion {#s4}
==========

Dengue fever has been described in historical records since 922 A.D. as a self-limiting febrile illness punctuated by joint pain and rash ([@B17], [@B18]). However, it was not until 1966 that DENV emerged in Pakistan where it was reported to cause non-specific febrile illness accompanied by gastrointestinal symptoms ([@B19]). DENV was not reported again in Pakistan until 1994 in Karachi where DENV1 and DENV2 were identified during a major outbreak ([@B20], [@B21]). In 2005, DENV3 was identified during an outbreak of DHF in Karachi ([@B22], [@B23]). By 2008, all 4 serotypes had been identified in Pakistan ([@B24]).

We identified co-infections of two DENV serotypes which, according to the literature, should have resulted in more severe manifestations of disease ([@B18], [@B25]--[@B27]). Our data show that only a single co-infection of DENV2 and DENV4 caused severe disease which appears to agree with other reports from India ([@B18]). Patients co-infected with DENV1 and DENV2 were symptomatically indistinguishable from patients infected with a single serotype. This also agrees with other reports that DENV1 co-infections do not result in severe forms of dengue fever ([@B18]). The window of detectable viremia via RT-PCR is 3--5 days. While it is possible that these patients were infected on separate occasions over a short duration of time to be detected via RT-PCR. These patients would systemically and immunologically progress as a co-infection from a single inoculation. The scenario that these patients were infected by a co-infected mosquito is much more likely as co-infection of vectors has been reported for DENV in multiple lab and field studies ([@B28]--[@B30]).

A noteworthy finding was the absence of DHF or other manifestations of severe dengue fever in our patients with secondary infections and all but 1 of the co-infected. A recent review of DENV infection in India showed that the overall percentage of severe DENV infection was 28.9% of all cases ([@B31]). DHF and severe DENV are reported at rates of 0.5--1% globally ([@B32]). The presence of a DENV-resistance gene has been proposed since numerous reports document the absence of DHF and severe DENV in persons of African descent, especially populations in Haiti ([@B33]--[@B36]). However, these theories have never been substantiated and the mechanism for this phenomenon are unknown. The relative absence of DHF in Pakistan and wide-spread occurrence of DHF in India reflect studies of the Caribbean islands and raises the question if there is a genetic or immunological factor in the population of Pakistan that confers resistance to severe DENV ([@B2], [@B34]--[@B36]).

The role of T cells in viral hemorrhagic fevers has not been characterized and the protective or pathogenic contribution of T cells is unclear ([@B37]). However, the protective role of memory CD8 cells presenting cross-reactive epitopes has been shown to protect against secondary DENV infections in endemic areas ([@B38], [@B39]). In addition, sequential flaviviral infections can also confer cross-protection against primary or secondary DENV infections ([@B40]).

Another plausible explanation could be that persistent exposure to co-circulating viral pathogens (DENV1--4, WNV, JEV) has corrupted the normal immune defenses of this population. Memory CD8 T cells have been shown to respond to antigens, independent of T cell receptors to pathogens that cause inflammation ([@B41]--[@B43]). This allows memory CD8 cells to contribute to the innate immune response by detecting changes in cytokine production and eliciting a defensive response ([@B44]--[@B46]). However, during chronic viral infections, CD8 cells become exhausted and lose their self-renewal properties and over time, become depleted ([@B41], [@B47], [@B48]). Exhausted CD8 cells also lose their ability to produce interferon-γ when exposed to cognate antigens ([@B49], [@B50]). It is theorized that this loss of antigenic recognition could be immunopathogenic and contribute to sustained chronic viral infections ([@B41]). It could be that CD8 exhaustion if contributing to the lack of enhanced immune response to subsequent DENV infections as a result of their antigenic cross-reactivity.

Another explanation may lie in the antigenic cross-reactivity of the 4 serotypes. Antibody-dependent enhancement of infection from prior exposures is accepted as the primary cause of DHF, DSS, and death ([@B2]). However, recent work from Nicaragua has shown that DENV antibodies can offer protection or susceptibility to enhancement that is dependent on antibody titer ([@B51]). Our data show that all four DENV serotypes continuously circulate in Pakistan which could result in secondary infections that occur during times when antibodies might offer protection instead of enhancement. The same can be said for Haiti where all 4 serotypes continuously circulate ([@B33]). Clearly, more research is warranted in this area.

This study used an orthogonal system of NS1 antigen detection followed by RT-PCR for DENV detection and subtyping. We were able to identify significantly more NS1 positive patients than RT-PCR likely due to the use of serum as our RNA source. A growing body of research is showing that recovery of viral RNA persists for much longer in urine, saliva, whole blood, and plasma ([@B52]--[@B54]). Although we did not perform any phylogenetic analysis, prior work has shown that all four DENV serotypes circulating in Pakistan are descendant from India ([@B55]). Interestingly, DENV emerged in India during 1963, just 3 years prior to the Pakistan emergence in 1966 ([@B25], [@B56]).

This study demonstrates that all 4 DENV serotypes are co-circulating and co-infecting in Pakistan. The data show that each DENV serotype displayed at least one symptom at a higher frequency than the other serotypes though unfortunately, the incidence of specific symptoms was not discreet and was identified at least once for all serotypes. However, if one applies the clinical data to the system, one can generalize how each serotype presents in febrile patients in Pakistan. DENV1 had the greatest impact on the liver with higher frequency of abnormal liver function tests; DENV2 affected the central nervous system and joints; DENV3 affected the urinary system and blood; and DENV4 caused headaches and rash. The ability of these 4 serotypes to occupy the same ecological niche has puzzled scientists for decades. Perhaps the ability for specific serotypes to preferentially infect specific cells contributes to their persistence in the environment. These viruses provide an opportunity for future studies in DENV pathogenesis.
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ALT

:   Alanine transaminase

AST

:   Aspartate transaminase

CHIKV

:   Chikungunya virus

DENV

:   Dengue virus

DHF

:   Dengue hemorrhagic fever

DSS

:   Dengue shock syndrome

JEV

:   Japanese encephalitis virus

PRNT

:   Plaque reduction neutralization test

WNV

:   West Nile virus

ZIKV

:   Zika virus.
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